Copyright
©The Author(s) 2019.
World J Stem Cells. Aug 26, 2019; 11(8): 548-564
Published online Aug 26, 2019. doi: 10.4252/wjsc.v11.i8.548
Published online Aug 26, 2019. doi: 10.4252/wjsc.v11.i8.548
Ref. | Administration route | Number of cells infused | Etiology or disease | Study design, n for total; groups | Follow-up period | Trial number | Results |
[110] | Intravenous | (4.0-4.5) × 108 | Decompensated liver cirrhosis | 103; 50 hUC-MSCs, 53 control | 52 wk | ChiCTR-ONC-12002103 | Decrease in AST, increase in ALB, TBIL, PT Improvement in MELD and Child-Pugh scores |
[56] | Intravenous | 0.5 × 106/kg Every 4 wk, 3 times | ACLF (HBV cirrhosis) | 43; 24 hUC-MSCs, 19 control | 72 wk | NCT01218464 | Improvement in MELD Increase in ALB, PT |
[111] | Intravenous | 0.5 × 106/kg Every 4 wk, 3 times | Cirrhosis (HBV) | 45; 30 hUC-MSCs, 15 control | 48 wk | NCT01220492 | Decrease in ascites. Increase in ALB, TBIL. Improvement in MELD. |
[112] | Intravenous | 0.5 × 106/kg Every 4 wk, 3 times | UDCA-resistant PBC | 7 | 48 wk | NCT01662973 | Decrease in ALP, γ-GT, fatigue, pruritus Improvement quality of life |
[113] | Intravenous | 1 × 106/kg; wk 1, 2, 4, 8, 12 and 16 | Ischemic-type biliary lesions | 82; 12 hUC-MSCs, 70 control | 96 wk | NCT02223897 | Decrease in BIL, ALP, γ-GT Improvement in graft survival |
[114] | Intravenous | 1 × 106/kg; Every 4 wk, 3 times | Liver transplant patients with acute graft rejection | 27; 14 hUC-MSCs, 13 control | 12 wk | NCT01690247 | Decrease in ALT, AST, TBIL, acute rejection Improvement in liver allograft histology |
Peripheral vein | 4.0 × 107/patient, 4 times | LC | 320 | 144 wk | NCT01573923 | Unknown | |
Unknown | Unknown | LC | 20 | 48 wk | NCT01342250 | Unknown | |
Peripheral vein | 1.0 × 105/kg, 4 times | Liver failure (HBV) | 120 | 48 wk | NCT01724398 | Unknown | |
Portal vein or hepatic artery | Unknown | LC | 200 | 48 wk | NCT01233102 | Unknown | |
Hepatic artery | Unknown | LC | 50 | 4 wk | NCT01224327 | Unknown | |
Hepatic artery | 1.0 × 106/kg | LC (HBV) | 240 | 48 wk | NCT01728727 | Unknown | |
Peripheral vein | 210 | 72 wk | NCT01844063 | Unknown | |||
Peripheral vein | Unknown | ACLF (HBV) | 261 | 52 wk | NCT02812121 | Unknown | |
Portal vein or hepatic artery | 2.0 × 107/patient, 4 times | LC | 20 | 48 wk | NCT02652351 | Unknown | |
Peripheral vein | 1.0 × 106/kg, 3 times | Liver failure (AIH) | 100 | 96 wk | NCT01661842 | Unknown | |
Lobe | 5.0 × 108/patient | LC | 40 | 96 wk | NCT02786017 | Unknown |
- Citation: Yin F, Wang WY, Jiang WH. Human umbilical cord mesenchymal stem cells ameliorate liver fibrosis in vitro and in vivo: From biological characteristics to therapeutic mechanisms. World J Stem Cells 2019; 11(8): 548-564
- URL: https://www.wjgnet.com/1948-0210/full/v11/i8/548.htm
- DOI: https://dx.doi.org/10.4252/wjsc.v11.i8.548